Drug intelligence / Profile preview

90Y-HAMS

Development stage: Unknown
Lead developer: Vivos Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intra-arterial, Intravenous

Overview

No specific information is available for "90Y-HAMS," but if it's related to Yttrium-90, it might be used in radiation therapy for cancer treatment, similar to other Yttrium-90 formulations. **Radiopharmaceuticals like Yttrium-90 are used in cancer therapy, particularly for treating certain cancers by delivering targeted radiation to tumors.**

Beyond the preview

Go deeper on 90Y-HAMS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 90Y-HAMS.

Explore the full profile